Healthcare expert Dr. Jonathan D. Quick discusses solutions to address the rapid rise of chronic illnesses in the developing world.

With extensive experience in public health management, having worked for the International Red Cross, among others, and as a doctor in emergency situations on the ground in Africa and Asia— Ann Aerts discusses the Novartis Foundation's new leprosy strategy.

What happens when a patient’s only treatment hope rests with a promising but not yet locally approved therapy? At Novartis, we are providing a lifeline of access to innovative medicines under review or not yet approved locally when no other treatment options are available.

John Tsai, Head of Global Drug Development and Chief Medical Officer, describes how he balances innovation and patient needs.

State-of-the-art Novartis manufacturing facility in Indianapolis fortifies the foundation of an entirely new paradigm in pharmaceutical drug delivery.

Jay Bradner discusses his vision for an open framework of scientific discovery at Novartis.

The race is on to find a new treatment before resistance to today’s drugs becomes widespread.

Gschwentner and Lackner discuss the advantages of their job share.

The culture of volunteerism is a fundamental part of the Novartis corporate ethos. Here’s a snapshot of our efforts over the years.